This Week in Intelligent Investing

The episode is reasonably packed with sector-specific ideas: the Arnold Ventures/FDA infiltration thesis, the ethical argument against a Huntington's phase 3 trial (placebo patients lose drug eligibility by the time they worsen), the cascade from drug approvals to tools multiples, and the 'AI creates a queue' framing. Some repetition and meandering reduce the density, but the practitioner-level detail on mechanism keeps it above average.

“The unethical piece is this is a disease that, where time is of the essence. And so if you deliver someone a placebo in a certain cohort and then they. Time goes on and they get worse, they no longer qualify for the drug.”

“AI is sort of this coiled spring. But in order for the fuse to be lit, like I said, you need some of these drugs approved because you can have as much AI as you want. Uh, it's a regulated industry that's government controlled”

Several genuinely non-standard arguments appear: the Arnold Ventures/MAHA ideological infiltration of the FDA, the regulatory ethics argument against an HD placebo trial, and the blunt 'the only way you break Eroom's law is changes in regulation, not technological disruption.' The AI takes are more familiar and the biotech bubble prediction is a common contrarian pose, pulling the score down.

“the FDA has um, for some, for some odd reason it's been ill infiltrated with the Maha movement. With a number of members of the FDA tied to Arnold Ventures”

“The only way you break your room's law is changes in regulation, not technological disruption.”

Peter Mantas is a genuine specialist biotech investor (GP/CIO) with a law background, deep FDA procedural knowledge, and a running public research track record - not a thought-leader or career podcast guest. He's not a biotech operator or founder who has taken a drug to market, which caps the score, but his practitioner depth and specificity are real.

“I got deep into the scientific literature, got deep into the legal procedure, the, the, the IP patents. I got deep into understanding how the FDA works from a procedural, administrative perspective.”

“I'll use AI as like my pocket biotech analyst to be like, hey, this stock is down. Why, what happened?”

Unusually strong for the format: named patient population figures by jurisdiction, specific price anchors ($3M AMT-130 vs. $7-9M lifetime HD standard-of-care), enterprise value multiples (12-15x vs. 5x), share float (61M), biomarker names (NFL), named regulators, named payer guidance (Centene), and named downstream tools companies with causal logic linking approvals to their multiples.

“In the US there's 30,000 people who have HD, maybe another a hundred thousand who are pre symptomatic...that's going to cost $3 million...In the UK there's about 8,000 people...EU is bigger than the US it's 40,000 people”

“Centene has draft guidance already approving AMT130. Like they're ready to go. And Centene is notorious for pushing back on everything.”

Elliot Turner's questions are genuinely substantive - introducing Eroom's Law, pressing on CRISPR commercial adoption dynamics, and probing AI capacity constraints - and add intellectual lift. The main host's contributions are softer and sometimes biographical. There is no real pushback or productive disagreement, and some claims go unchallenged, keeping this from scoring higher.

“I've been having this theory that like between CRISPR Genomics and AI, you could finally break Earms law.”

“So then is there enough capacity in the system from the top with capital all the way down through the actual companies that run the clinical trials for biotechs to get more molecules into the clinic”